10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results

Provides Outlook for 2026 with Continued Growth Driven by New Partnerships and Product Innovations

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

10x Genomics, a leader in single cell and spatial biology, reported its financial results for the fourth quarter and full year ended December 31, 2025. The company saw a 1% increase in revenue for Q4 2025 compared to the prior year, and a 5% increase in full-year revenue, driven by new partnerships and product launches. 10x Genomics ended the year with a strong cash position and is optimistic about continued growth in 2026 fueled by AI-driven demand, translational research, and emerging clinical opportunities.

Why it matters

10x Genomics is a key player in the rapidly evolving field of single cell and spatial biology, which is transforming the understanding of health and disease. The company's financial performance and strategic partnerships highlight its ability to drive innovation and commercialize its technologies, positioning it well for future growth in the life sciences market.

The details

10x Genomics reported revenue of $166.0 million for Q4 2025, a 1% increase over the prior year period. For the full year 2025, revenue was $642.8 million, a 5% increase from 2024. Excluding non-recurring revenue from patent litigation settlements, full-year revenue was $598.7 million, a 2% decrease. The company saw improved gross margins and reduced operating expenses, leading to a narrower net loss compared to 2024. 10x Genomics also announced several key partnerships and initiatives, including collaborations with the Cancer Research Institute, PharosAI, and Dana-Farber Cancer Institute to advance cancer research and diagnostics.

  • 10x Genomics reported its Q4 2025 and full-year 2025 financial results on February 12, 2026.
  • The company provided its outlook for the full year 2026.

The players

10x Genomics, Inc.

A life science technology company building products to accelerate the mastery of biology and advance human health, with a focus on single cell and spatial biology.

Serge Saxonov

Co-founder and CEO of 10x Genomics.

Cancer Research Institute

A non-profit organization dedicated to advancing the development of immunotherapies for the treatment of cancer.

PharosAI

A company that develops AI-powered solutions for drug discovery and diagnostics.

Dana-Farber Cancer Institute

A comprehensive cancer center in Boston, Massachusetts, focused on cancer research and patient care.

Got photos? Submit your photos here. ›

What they’re saying

“In 2025, our team executed with discipline through a challenging environment while continuing to strengthen the fundamentals of the business. As we look to 2026, I am excited by the expanding impact of our platforms, driven by new product innovations and strategic partnerships. We are well positioned to execute across multiple growth vectors in the business, especially AI-driven demand, translational research and emerging clinical opportunities.”

— Serge Saxonov, Co-founder and CEO (10x Genomics)

What’s next

10x Genomics expects full year 2026 revenue to be in the range of $600 million to $625 million, representing 0% to 4% growth over 2025 excluding non-recurring revenue.

The takeaway

10x Genomics' strong financial performance and strategic partnerships demonstrate its ability to drive innovation and commercialize its technologies in the rapidly evolving field of single cell and spatial biology, positioning the company for continued growth and impact in the life sciences market.